$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000114420416079982 Filed on February 09, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2015 Q1
Revenue	$5.195M	$2.194M	$1.234M
YoY Change	320.99%	60.97%	20.04%
Cost Of Revenue	$1.036M	$836.0K	$904.0K
YoY Change	14.6%	19.43%	-13.58%
Gross Profit	$4.159M	$1.358M	$331.0K
YoY Change	1156.5%	104.83%	-1938.89%
Gross Profit Margin	80.06%	61.9%	26.82%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development		$3.174M
YoY Change		38.44%
% of Gross Profit		233.75%
Depreciation & Amortization	$180.0K	$160.0K	-$70.00K
YoY Change	-357.14%	-23.81%	-158.33%
% of Gross Profit	4.33%	11.78%	-21.15%
Operating Expenses	$3.588M	$4.071M	$5.788M
YoY Change	-38.01%	26.39%	144.74%
Operating Profit	$571.0K	-$2.713M	-$5.457M
YoY Change	-110.46%	6.1%	128.9%
Interest Expense		$68.12K
YoY Change		2.97%
% of Operating Profit
Other Income/Expense, Net	$7.408M	-$9.520M	-$898.0K
YoY Change	-924.94%	-195.45%	-97.16%
Pretax Income
YoY Change
Income Tax	-$520.0K	$0.00	-$3.000K
% Of Pretax Income
Net Earnings	$8.499M	-$12.23M	-$6.350M
YoY Change	-233.84%	-264.93%	-92.68%
Net Earnings / Revenue	163.6%	-557.57%	-514.59%
Basic Earnings Per Share	$0.03	-$0.05	-$0.01
Diluted Earnings Per Share	$0.00	-$0.05	-$0.01
COMMON SHARES
Basic Shares Outstanding	695.2M shares	684.8M shares
Diluted Shares Outstanding		836.5M shares

Balance Sheet

Concept	2016 Q1	2015 Q4	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.51M	$8.100M	$7.460M
YoY Change	54.29%	-2.06%	7.49%
Cash & Equivalents	$11.51M	$8.103M	$7.464M
Short-Term Investments
Other Short-Term Assets	$380.0K	$390.0K	$390.0K
YoY Change	-2.56%	18.18%	21.88%
Inventory	$3.294M	$3.180M	$3.032M
Prepaid Expenses
Receivables	$1.530M	$750.0K	$1.446M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$16.71M	$12.42M	$12.33M
YoY Change	35.55%	-5.84%	24.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.111M	$7.660M	$6.402M
YoY Change	26.69%	39.78%	52.44%
Goodwill
YoY Change
Intangibles	$6.412M		$6.382M
YoY Change	0.47%		0.5%
Long-Term Investments	$50.00K	$50.00K	$200.0K
YoY Change	-75.0%	-16.67%	-94.03%
Other Assets	$437.7K	$645.6K	$806.0K
YoY Change	-45.7%	-3.35%	-79.03%
Total Long-Term Assets	$14.96M	$14.71M	$13.59M
YoY Change	10.09%	17.59%	-5.58%
TOTAL ASSETS
Total Short-Term Assets	$16.71M	$12.42M	$12.33M
Total Long-Term Assets	$14.96M	$14.71M	$13.59M
Total Assets	$31.67M	$27.13M	$25.92M
YoY Change	22.2%	5.57%	6.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.804M	$3.040M	$3.384M
YoY Change	-46.67%	-5.3%	53.1%
Accrued Expenses	$555.4K		$614.0K
YoY Change	-9.55%
Deferred Revenue
YoY Change
Short-Term Debt	$34.68K	$720.0K	$0.00
YoY Change		7.46%	-100.0%
Long-Term Debt Due	$308.3K	$590.0K	$265.2K
YoY Change	16.25%	28.26%	202.79%
Total Short-Term Liabilities	$4.640M	$5.360M	$5.069M
YoY Change	-8.46%	23.22%	-17.72%
LONG-TERM LIABILITIES
Long-Term Debt	$2.180M	$1.850M	$2.070M
YoY Change	5.31%	-10.63%	10869.79%
Other Long-Term Liabilities	$47.42K	$21.99M	$629.1K
YoY Change	-92.46%	4634.86%	379.73%
Total Long-Term Liabilities	$15.87M	$23.84M	$20.58M
YoY Change	-22.89%	-54.05%	-79.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.640M	$5.360M	$5.069M
Total Long-Term Liabilities	$15.87M	$23.84M	$20.58M
Total Liabilities	$20.51M	$29.20M	$25.65M
YoY Change	-20.04%	-48.08%	-75.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$142.7M		-$142.0M
YoY Change	0.48%		-36.9%
Common Stock	$109.8M		$107.6M
YoY Change	2.13%		-25.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K		$306.8K
YoY Change	0.0%		0.0%
Treasury Stock Shares	100.0K shares	100.0K shares	100.0K shares
Shareholders Equity	-$33.12M	-$2.070M	-$34.73M
YoY Change
Total Liabilities & Shareholders Equity	$31.67M	$27.13M	$25.92M
YoY Change	22.2%	5.56%	6.59%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2015 Q1
OPERATING ACTIVITIES
Net Income	$8.499M	-$12.23M	-$6.350M
YoY Change	-233.84%	-264.93%	-92.68%
Depreciation, Depletion And Amortization	$180.0K	$160.0K	-$70.00K
YoY Change	-357.14%	-23.81%	-158.33%
Cash From Operating Activities	$600.0K	-$1.780M	-$3.850M
YoY Change	-115.58%	-31.8%	160.14%
INVESTING ACTIVITIES
Capital Expenditures	-$570.0K	$40.00K	-$600.0K
YoY Change	-5.0%	-110.26%	361.54%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$570.0K	$40.00K	-$600.0K
YoY Change	-5.0%	-110.53%	757.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.370M	810.0K	3.650M
YoY Change	-7.67%	-77.75%	-50.68%
NET CHANGE
Cash From Operating Activities	600.0K	-1.780M	-3.850M
Cash From Investing Activities	-570.0K	40.00K	-600.0K
Cash From Financing Activities	3.370M	810.0K	3.650M
Net Change In Cash	3.400M	-930.0K	-800.0K
YoY Change	-525.0%	-243.08%	-113.68%
FREE CASH FLOW
Cash From Operating Activities	$600.0K	-$1.780M	-$3.850M
Capital Expenditures	-$570.0K	$40.00K	-$600.0K
Free Cash Flow	$1.170M	-$1.820M	-$3.250M
YoY Change	-136.0%	-18.02%	140.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Deferred Long Term Liability Charges DeferredLongTermLiabilityCharges	17762573	USD
	us-gaap	Interest Expense InterestExpense	204626	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	21161859	USD
CY2015Q4	us-gaap	Deferred Long Term Liability Charges DeferredLongTermLiabilityCharges	17850570	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-295375	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	5851020	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	37994786	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	961401	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1452468	USD
	us-gaap	Contracts Revenue ContractsRevenue	5000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
	us-gaap	Contracts Revenue ContractsRevenue	0	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Gross Profit GrossProfit	3856316	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9878465	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	750872145	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1991219	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	166647	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	246495	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	683663	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	492625	USD
	us-gaap	Operating Expenses OperatingExpenses	12721068	USD
	us-gaap	Operating Expenses OperatingExpenses	12742962	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11049921	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8886646	USD
	us-gaap	Interest Expense InterestExpense	214434	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-87999	USD
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1670678	USD
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3248	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2750	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22621351	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	581375865	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	665720299	shares
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7464180	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	388959	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1446441	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6401802	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6381774	USD
CY2015Q4	us-gaap	Security Deposit SecurityDeposit	48714	USD
CY2015Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	207945	USD
CY2015Q4	us-gaap	Assets Assets	27130873	USD
CY2015Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	220000	USD
CY2015Q4	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	374546	USD
CY2015Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	718309	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3038115	USD
CY2015Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1845000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1013333	USD
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	695168934	shares
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	806019	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	3032002	USD
	dei	Trading Symbol TradingSymbol	ELTP
CY2015Q1	us-gaap	Assets Current AssetsCurrent	12330684	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	388061	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	645618	USD
CY2015Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2065000	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	125557	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3781000	USD
	us-gaap	Gross Profit GrossProfit	1671147	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	7303488	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2109853	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3447172	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	586167	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3532223	USD
CY2015Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	583071	USD
CY2015Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3997528	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10012623	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1992293	USD
CY2014Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2850459	USD
CY2015Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	58771	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	122772	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	817481642	shares
CY2014Q4	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1014628	USD
CY2015Q4	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1622052	USD
CY2014Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	348273	USD
CY2015Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	571824	USD
CY2014Q4	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2015Q4	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1362901	USD
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	2193876	USD
CY2014Q4	us-gaap	Cost Of Revenue CostOfRevenue	699654	USD
CY2015Q4	us-gaap	Cost Of Revenue CostOfRevenue	835675	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	663247	USD
CY2015Q4	us-gaap	Gross Profit GrossProfit	1358201	USD
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2292957	USD
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3174311	USD
CY2014Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	89505	USD
CY2015Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75025	USD
CY2014Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	212967	USD
CY2015Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	166825	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	3220558	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	4071000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2557311	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2712799	USD
CY2014Q4	us-gaap	Interest Expense InterestExpense	66153	USD
CY2015Q4	us-gaap	Interest Expense InterestExpense	68119	USD
CY2014Q4	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	10040234	USD
CY2015Q4	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-9452046	USD
CY2014Q4	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2015Q4	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2015Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9974081	USD
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9520165	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21016770	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37018704	USD
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	601109708	shares
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	684773829	shares
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	770605988	shares
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	836535171	shares
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-12232964	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	7416770	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9182021	USD
	us-gaap	Net Income Loss NetIncomeLoss	11571430	USD
CY2015Q4	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	-24785740	USD
CY2014Q4	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	13600000	USD
	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	-23428573	USD
	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	26423356	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3289198	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	246494	USD
	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	2432002	USD
	eltp	Park Capital Purchase Agreement ParkCapitalPurchaseAgreement	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9590429	USD
CY2015Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	eltp	Stock Issued During Period Value Payment Of Directors Fees StockIssuedDuringPeriodValuePaymentOfDirectorsFees	12500	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	648505	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-16488	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	29200	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1206	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1136	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-816579	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	149611	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-148712	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	346007	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	4406666	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3371847	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11246722	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1378005	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3478046	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1351847	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	26158	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	123912	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	5000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3289198	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9678329	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2455753	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	545086	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	281237	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	133354	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	16364	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5388952	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9100828	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	639100	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1332152	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6941777	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8273929	USD
	us-gaap	Interest Paid InterestPaid	142772	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	642477	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	786527	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2272500	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	210000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1110000	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	117095	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Redemption Value RedeemableNoncontrollingInterestEquityPreferredRedemptionValue	-23428573	USD
CY2014Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Redemption Value RedeemableNoncontrollingInterestEquityPreferredRedemptionValue	26423356	USD
	eltp	Proceeds From Sale Of Branded Products ProceedsFromSaleOfBrandedProducts	0	USD
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	26158	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	206892	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	206892	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	90427	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	108216	USD
CY2015Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45214	USD
CY2014Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45214	USD
CY2015Q4	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-5496	USD
CY2014Q4	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	24010	USD
CY2015Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	31533	USD
CY2015Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	37027	USD
CY2015Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	26038	USD
CY2014Q3	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	35000	sqft
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4743000	shares
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2566667	shares
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-32610594	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2015Q4	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-37018704	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2623464	USD
CY2014Q4	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	23640234	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	47585215	USD
CY2014Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	169496280	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	169496280	shares
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14212465	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12475938	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6556108	USD
	us-gaap	Depreciation Depreciation	492625	USD
	us-gaap	Depreciation Depreciation	683663	USD
CY2015Q4	eltp	Fixed Assets Not Yet Been Placed In Service FixedAssetsNotYetBeenPlacedInService	2170000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	272620	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6074117	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2015Q4	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	146508	USD
CY2015Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	135874	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	688164807	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631160701	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	687164807	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	630060701	shares
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23751	USD
CY2015Q4	eltp	Proceeds From Sale Of Generic Products ProceedsFromSaleOfGenericProducts	6720000	USD
	eltp	Proceeds From Sale Of Generic Products ProceedsFromSaleOfGenericProducts	1954000	USD
CY2015Q4	eltp	Proceeds From Sale Of Branded Products ProceedsFromSaleOfBrandedProducts	0	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6349919	USD
CY2015	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	31855	USD
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
	eltp	Milestone Issued Value For Epic Strategic Alliance Agreement MilestoneIssuedValueForEpicStrategicAllianceAgreement	840000	USD
	eltp	Milestone Issued For Epic Strategic Alliance Agreement Value MilestoneIssuedForEpicStrategicAllianceAgreementValue	0	USD
CY2015Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	15000	acre
	eltp	Lease Period Description LeasePeriodDescription	The lease term began on July 1, 2010.
	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	include an initial term that expires on December 31, 2016, and the Company has the option to renew the lease for two additional terms of five years each.
	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	The milestones, totaling $500k, consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 &amp; 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
	us-gaap	Finite Lived Intangible Assets Amortization Method FiniteLivedIntangibleAssetsAmortizationMethod	straight-line method
	us-gaap	Interest Paid InterestPaid	127912	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	384699	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	37067	USD
	eltp	Milestone Issued For Epic Strategic Alliance Agreement Value MilestoneIssuedForEpicStrategicAllianceAgreementValue	840000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1533080	USD
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	58428575	USD
CY2015Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	35000000	USD

Files In Submission

Name	View Source	Status
0001144204-16-079982-index-headers.html	Edgar Link	pending
0001144204-16-079982-index.html	Edgar Link	pending
0001144204-16-079982.txt	Edgar Link	pending
0001144204-16-079982-xbrl.zip	Edgar Link	pending
eltp-20151231.xml	Edgar Link	completed
eltp-20151231.xsd	Edgar Link	pending
eltp-20151231_cal.xml	Edgar Link	unprocessable
eltp-20151231_def.xml	Edgar Link	unprocessable
eltp-20151231_lab.xml	Edgar Link	unprocessable
eltp-20151231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v430167_10q.htm	Edgar Link	pending
v430167_ex31-1.htm	Edgar Link	pending
v430167_ex31-2.htm	Edgar Link	pending
v430167_ex32-1.htm	Edgar Link	pending
v430167_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2016 Q1 Form 10-Q Financial Statement

#000114420416079982 Filed on February 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2016 Q1 Form 10-Q Financial Statement

#000114420416079982 Filed on February 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp